SAB Biotherapeutics, Inc.
General ticker "SABS" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $21.7M (TTM average)
SAB Biotherapeutics, Inc. follows the US Stock Market performance with the rate: 25.4%.
Estimated limits based on current volatility of 3.8%: low 3.60$, high 3.89$
Factors to consider:
- Total employees count: 57 as of 2023
- Top business risk factors: Economic downturns and volatility, Regulatory and compliance, Market competition, Manufacturing scale up, Labor/talent shortage/retention
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [2.31$, 6.20$]
- 2025-12-31 to 2026-12-31 estimated range: [2.03$, 5.54$]
Financial Metrics affecting the SABS estimates:
- Positive: with PPE of -1.1 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -91.12 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Negative: negative Net income
- Positive: 41.86 < Shareholder equity ratio, % of 58.76 <= 63.39
Short-term SABS quotes
Long-term SABS plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $23.90MM | $2.24MM | $1.32MM |
| Operating Expenses | $52.82MM | $40.31MM | $44.23MM |
| Operating Income | $-28.92MM | $-38.08MM | $-42.91MM |
| Non-Operating Income | $10.20MM | $-4.12MM | $8.81MM |
| Interest Expense | $0.30MM | $0.32MM | $0.32MM |
| R&D Expense | $36.44MM | $16.52MM | $30.16MM |
| Income(Loss) | $-18.72MM | $-42.19MM | $-34.11MM |
| Taxes | $0.03MM | $0.00MM | $0.00MM |
| Profit(Loss)* | $-18.74MM | $-42.19MM | $-34.11MM |
| Stockholders Equity | $31.06MM | $57.30MM | $25.97MM |
| Assets | $50.90MM | $83.94MM | $44.20MM |
| Operating Cash Flow | $-23.46MM | $-25.12MM | $-34.29MM |
| Capital expenditure | $2.17MM | $0.20MM | $0.34MM |
| Investing Cash Flow | $-2.09MM | $-0.15MM | $-11.96MM |
| Financing Cash Flow | $1.05MM | $66.77MM | $-1.17MM |
| Earnings Per Share** | $-4.31 | $-7.64 | $-3.68 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.